SEC Form 4															
FOI	RM 4	UNITEI	NITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549												
Section 16. Fo	t if no longer subject to rm 4 or Form 5 y continue. See ).	Filed pursua	F CHANGES Int to Section 16(a) ( Int to 30(h) of the In	es Exchange /	_			ber: average burd response:	3235-0287 en 0.5						
1. Name and Address of Reporting Person <sup>*</sup> Barnett Valerie				er Name <b>and</b> Ticke k Bioscience			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner V Officer (give title Other (specify								
	(Last) (First) (Middle) C/O CYTEK BIOSCIENCES, INC. 47215 LAKEVIEW BOULEVARD				3. Date of Earliest Transaction (Month/Day/Year) 08/18/2022							General Counsel			
(Street)		94538	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Indiv Line) X						
(City)	(State)	(Zip) Table I - Nor	n-Derivative S	Securities Acq	uired,	Dis	bosed of, c	or Ben	eficially	Owned					
1. Title of Security (Instr. 3) 2. Transa Date			2. Transaction	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)				(A) or	5. Amount of Securities Beneficially Owned Followin Reported	For (D)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)					

## 08/18/2022 Common Stock 2,016 (1) 18,667(2) D М Α Common Stock 08/18/2022 F 786(3) D \$14.06 17,881 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

( <b>3</b> , <b>P</b> , <b>-------------</b>															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	(1)	08/18/2022		М			2,016	(4)	(4)	Common Stock	2,016	\$0.00	27,554	D	

## Explanation of Responses:

1. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2. Includes 2,610 shares acquired by the Reporting Person under the Issuer's 2021 Employee Stock Purchase Plan on May 31, 2022.

3. Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.

4. The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18.

Remarks:

/s/ Valerie Barnett

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.



Date